Investors Buy High Volume of Hims & Hers Health Call Options (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) was the target of unusually large options trading activity on Tuesday. Investors bought 28,871 call options on the stock. This represents an increase of approximately 249% compared to the average daily volume of 8,272 call options.

Analysts Set New Price Targets

Several research firms recently weighed in on HIMS. Leerink Partnrs reaffirmed a “market perform” rating on shares of Hims & Hers Health in a research report on Monday, February 26th. Imperial Capital raised shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price target for the company in a report on Wednesday, February 28th. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price objective on the stock. Truist Financial boosted their price objective on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Finally, TheStreet raised Hims & Hers Health from a “d” rating to a “c” rating in a report on Monday, March 4th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Hims & Hers Health currently has an average rating of “Moderate Buy” and a consensus target price of $15.07.

Hims & Hers Health Stock Up 6.1 %

NYSE HIMS opened at $12.36 on Wednesday. Hims & Hers Health has a twelve month low of $5.65 and a twelve month high of $17.16. The business’s fifty day moving average is $14.04 and its 200 day moving average is $10.35. The company has a market cap of $2.65 billion, a price-to-earnings ratio of -112.27 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The firm had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. During the same period last year, the firm posted ($0.05) earnings per share. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. On average, research analysts anticipate that Hims & Hers Health will post 0.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 97,208 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total value of $931,252.64. Following the sale, the chief executive officer now owns 51,653 shares of the company’s stock, valued at $494,835.74. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Hims & Hers Health news, CEO Andrew Dudum sold 97,208 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total transaction of $931,252.64. Following the completion of the sale, the chief executive officer now owns 51,653 shares of the company’s stock, valued at approximately $494,835.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 4,080 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40. Following the sale, the insider now owns 154,345 shares of the company’s stock, valued at $1,548,080.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 736,191 shares of company stock worth $9,733,700. 31.63% of the stock is owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors have recently added to or reduced their stakes in HIMS. FNY Investment Advisers LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter worth $48,000. Cornerstone Investment Partners LLC bought a new position in Hims & Hers Health during the 1st quarter worth $161,000. EMC Capital Management lifted its holdings in Hims & Hers Health by 80.0% during the 3rd quarter. EMC Capital Management now owns 12,000 shares of the company’s stock worth $79,000 after buying an additional 5,332 shares during the period. Belpointe Asset Management LLC bought a new stake in shares of Hims & Hers Health in the 3rd quarter valued at about $76,000. Finally, Certuity LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $109,000. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.